The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Immuno-oncology Diagnosis-Global Market Insights and Sales Trends 2024
Synopsis
The global Immuno-oncology Diagnosis market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Immuno-oncology Diagnosis in various end use industries. The expanding demands from the Research and Diagnostics, are propelling Immuno-oncology Diagnosis market. PCR, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the NGS segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Immuno-oncology Diagnosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Immuno-oncology Diagnosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Immuno-oncology Diagnosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Immuno-oncology Diagnosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Immuno-oncology Diagnosis covered in this report include 10x Genomics, Abbott Laboratories, Abcam, Adaptive Biotechnologies, Aethlon Medical, Agena Bioscience, Angle plc, Apocell and ARUP Laboratories, etc.
The global Immuno-oncology Diagnosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
10x Genomics
Abbott Laboratories
Abcam
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience
Angle plc
Apocell
ARUP Laboratories
Beckman Coulter
Becton Dickinson
Bioarray Genetics
BioCartis
Biocept
Biodesix Inc
BioFluidica
BioGenex 40 bioMérieux
Bio-Rad
Bio-Techne
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Charles River Laboratories
Chronix Biomedical
Circulogene
Clearbridge BioMedics
Clinical Genomics
Pfizer
Promega
Protagen Diagnostics
Qiagen
Quanterix
Rarecells SAS
Roche Diagnostics
Siemens
Global Immuno-oncology Diagnosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Immuno-oncology Diagnosis market, Segment by Type:
PCR
NGS
Immunoassay
Global Immuno-oncology Diagnosis market, by Application
Research
Diagnostics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Immuno-oncology Diagnosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Immuno-oncology Diagnosis market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Immuno-oncology Diagnosis in various end use industries. The expanding demands from the Research and Diagnostics, are propelling Immuno-oncology Diagnosis market. PCR, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the NGS segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Immuno-oncology Diagnosis, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Immuno-oncology Diagnosis market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Immuno-oncology Diagnosis market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Immuno-oncology Diagnosis sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Immuno-oncology Diagnosis covered in this report include 10x Genomics, Abbott Laboratories, Abcam, Adaptive Biotechnologies, Aethlon Medical, Agena Bioscience, Angle plc, Apocell and ARUP Laboratories, etc.
The global Immuno-oncology Diagnosis market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
10x Genomics
Abbott Laboratories
Abcam
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience
Angle plc
Apocell
ARUP Laboratories
Beckman Coulter
Becton Dickinson
Bioarray Genetics
BioCartis
Biocept
Biodesix Inc
BioFluidica
BioGenex 40 bioMérieux
Bio-Rad
Bio-Techne
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
CellMax Life
Charles River Laboratories
Chronix Biomedical
Circulogene
Clearbridge BioMedics
Clinical Genomics
Pfizer
Promega
Protagen Diagnostics
Qiagen
Quanterix
Rarecells SAS
Roche Diagnostics
Siemens
Global Immuno-oncology Diagnosis market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Immuno-oncology Diagnosis market, Segment by Type:
PCR
NGS
Immunoassay
Global Immuno-oncology Diagnosis market, by Application
Research
Diagnostics
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Immuno-oncology Diagnosis companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Immuno-oncology Diagnosis
1.1 Immuno-oncology Diagnosis Market Overview
1.1.1 Immuno-oncology Diagnosis Product Scope
1.1.2 Immuno-oncology Diagnosis Market Status and Outlook
1.2 Global Immuno-oncology Diagnosis Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Immuno-oncology Diagnosis Market Size by Region (2018-2029)
1.4 Global Immuno-oncology Diagnosis Historic Market Size by Region (2018-2023)
1.5 Global Immuno-oncology Diagnosis Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Immuno-oncology Diagnosis Market Size (2018-2029)
1.6.1 North America Immuno-oncology Diagnosis Market Size (2018-2029)
1.6.2 Europe Immuno-oncology Diagnosis Market Size (2018-2029)
1.6.3 Asia-Pacific Immuno-oncology Diagnosis Market Size (2018-2029)
1.6.4 Latin America Immuno-oncology Diagnosis Market Size (2018-2029)
1.6.5 Middle East & Africa Immuno-oncology Diagnosis Market Size (2018-2029)
2 Immuno-oncology Diagnosis Market by Type
2.1 Introduction
2.1.1 PCR
2.1.2 NGS
2.1.3 Immunoassay
2.2 Global Immuno-oncology Diagnosis Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Immuno-oncology Diagnosis Historic Market Size by Type (2018-2023)
2.2.2 Global Immuno-oncology Diagnosis Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Immuno-oncology Diagnosis Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Immuno-oncology Diagnosis Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Immuno-oncology Diagnosis Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Immuno-oncology Diagnosis Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Immuno-oncology Diagnosis Revenue Breakdown by Type (2018-2029)
3 Immuno-oncology Diagnosis Market Overview by Application
3.1 Introduction
3.1.1 Research
3.1.2 Diagnostics
3.2 Global Immuno-oncology Diagnosis Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Immuno-oncology Diagnosis Historic Market Size by Application (2018-2023)
3.2.2 Global Immuno-oncology Diagnosis Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Immuno-oncology Diagnosis Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Immuno-oncology Diagnosis Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Immuno-oncology Diagnosis Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Immuno-oncology Diagnosis Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Immuno-oncology Diagnosis Revenue Breakdown by Application (2018-2029)
4 Immuno-oncology Diagnosis Competition Analysis by Players
4.1 Global Immuno-oncology Diagnosis Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immuno-oncology Diagnosis as of 2022)
4.3 Date of Key Players Enter into Immuno-oncology Diagnosis Market
4.4 Global Top Players Immuno-oncology Diagnosis Headquarters and Area Served
4.5 Key Players Immuno-oncology Diagnosis Product Solution and Service
4.6 Competitive Status
4.6.1 Immuno-oncology Diagnosis Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 10x Genomics
5.1.1 10x Genomics Profile
5.1.2 10x Genomics Main Business
5.1.3 10x Genomics Immuno-oncology Diagnosis Products, Services and Solutions
5.1.4 10x Genomics Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.1.5 10x Genomics Recent Developments
5.2 Abbott Laboratories
5.2.1 Abbott Laboratories Profile
5.2.2 Abbott Laboratories Main Business
5.2.3 Abbott Laboratories Immuno-oncology Diagnosis Products, Services and Solutions
5.2.4 Abbott Laboratories Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.2.5 Abbott Laboratories Recent Developments
5.3 Abcam
5.3.1 Abcam Profile
5.3.2 Abcam Main Business
5.3.3 Abcam Immuno-oncology Diagnosis Products, Services and Solutions
5.3.4 Abcam Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.3.5 Adaptive Biotechnologies Recent Developments
5.4 Adaptive Biotechnologies
5.4.1 Adaptive Biotechnologies Profile
5.4.2 Adaptive Biotechnologies Main Business
5.4.3 Adaptive Biotechnologies Immuno-oncology Diagnosis Products, Services and Solutions
5.4.4 Adaptive Biotechnologies Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.4.5 Adaptive Biotechnologies Recent Developments
5.5 Aethlon Medical
5.5.1 Aethlon Medical Profile
5.5.2 Aethlon Medical Main Business
5.5.3 Aethlon Medical Immuno-oncology Diagnosis Products, Services and Solutions
5.5.4 Aethlon Medical Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.5.5 Aethlon Medical Recent Developments
5.6 Agena Bioscience
5.6.1 Agena Bioscience Profile
5.6.2 Agena Bioscience Main Business
5.6.3 Agena Bioscience Immuno-oncology Diagnosis Products, Services and Solutions
5.6.4 Agena Bioscience Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.6.5 Agena Bioscience Recent Developments
5.7 Angle plc
5.7.1 Angle plc Profile
5.7.2 Angle plc Main Business
5.7.3 Angle plc Immuno-oncology Diagnosis Products, Services and Solutions
5.7.4 Angle plc Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.7.5 Angle plc Recent Developments
5.8 Apocell
5.8.1 Apocell Profile
5.8.2 Apocell Main Business
5.8.3 Apocell Immuno-oncology Diagnosis Products, Services and Solutions
5.8.4 Apocell Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.8.5 Apocell Recent Developments
5.9 ARUP Laboratories
5.9.1 ARUP Laboratories Profile
5.9.2 ARUP Laboratories Main Business
5.9.3 ARUP Laboratories Immuno-oncology Diagnosis Products, Services and Solutions
5.9.4 ARUP Laboratories Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.9.5 ARUP Laboratories Recent Developments
5.10 Beckman Coulter
5.10.1 Beckman Coulter Profile
5.10.2 Beckman Coulter Main Business
5.10.3 Beckman Coulter Immuno-oncology Diagnosis Products, Services and Solutions
5.10.4 Beckman Coulter Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.10.5 Beckman Coulter Recent Developments
5.11 Becton Dickinson
5.11.1 Becton Dickinson Profile
5.11.2 Becton Dickinson Main Business
5.11.3 Becton Dickinson Immuno-oncology Diagnosis Products, Services and Solutions
5.11.4 Becton Dickinson Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.11.5 Becton Dickinson Recent Developments
5.12 Bioarray Genetics
5.12.1 Bioarray Genetics Profile
5.12.2 Bioarray Genetics Main Business
5.12.3 Bioarray Genetics Immuno-oncology Diagnosis Products, Services and Solutions
5.12.4 Bioarray Genetics Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.12.5 Bioarray Genetics Recent Developments
5.13 BioCartis
5.13.1 BioCartis Profile
5.13.2 BioCartis Main Business
5.13.3 BioCartis Immuno-oncology Diagnosis Products, Services and Solutions
5.13.4 BioCartis Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.13.5 BioCartis Recent Developments
5.14 Biocept
5.14.1 Biocept Profile
5.14.2 Biocept Main Business
5.14.3 Biocept Immuno-oncology Diagnosis Products, Services and Solutions
5.14.4 Biocept Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.14.5 Biocept Recent Developments
5.15 Biodesix Inc
5.15.1 Biodesix Inc Profile
5.15.2 Biodesix Inc Main Business
5.15.3 Biodesix Inc Immuno-oncology Diagnosis Products, Services and Solutions
5.15.4 Biodesix Inc Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.15.5 Biodesix Inc Recent Developments
5.16 BioFluidica
5.16.1 BioFluidica Profile
5.16.2 BioFluidica Main Business
5.16.3 BioFluidica Immuno-oncology Diagnosis Products, Services and Solutions
5.16.4 BioFluidica Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.16.5 BioFluidica Recent Developments
5.17 BioGenex 40 bioMérieux
5.17.1 BioGenex 40 bioMérieux Profile
5.17.2 BioGenex 40 bioMérieux Main Business
5.17.3 BioGenex 40 bioMérieux Immuno-oncology Diagnosis Products, Services and Solutions
5.17.4 BioGenex 40 bioMérieux Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.17.5 BioGenex 40 bioMérieux Recent Developments
5.18 Bio-Rad
5.18.1 Bio-Rad Profile
5.18.2 Bio-Rad Main Business
5.18.3 Bio-Rad Immuno-oncology Diagnosis Products, Services and Solutions
5.18.4 Bio-Rad Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.18.5 Bio-Rad Recent Developments
5.19 Bio-Techne
5.19.1 Bio-Techne Profile
5.19.2 Bio-Techne Main Business
5.19.3 Bio-Techne Immuno-oncology Diagnosis Products, Services and Solutions
5.19.4 Bio-Techne Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.19.5 Bio-Techne Recent Developments
5.20 Bristol-Myers Squibb
5.20.1 Bristol-Myers Squibb Profile
5.20.2 Bristol-Myers Squibb Main Business
5.20.3 Bristol-Myers Squibb Immuno-oncology Diagnosis Products, Services and Solutions
5.20.4 Bristol-Myers Squibb Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.20.5 Bristol-Myers Squibb Recent Developments
5.21 Cancer Genetics
5.21.1 Cancer Genetics Profile
5.21.2 Cancer Genetics Main Business
5.21.3 Cancer Genetics Immuno-oncology Diagnosis Products, Services and Solutions
5.21.4 Cancer Genetics Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.21.5 Cancer Genetics Recent Developments
5.22 Caris Molecular Diagnostics
5.22.1 Caris Molecular Diagnostics Profile
5.22.2 Caris Molecular Diagnostics Main Business
5.22.3 Caris Molecular Diagnostics Immuno-oncology Diagnosis Products, Services and Solutions
5.22.4 Caris Molecular Diagnostics Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.22.5 Caris Molecular Diagnostics Recent Developments
5.23 CellMax Life
5.23.1 CellMax Life Profile
5.23.2 CellMax Life Main Business
5.23.3 CellMax Life Immuno-oncology Diagnosis Products, Services and Solutions
5.23.4 CellMax Life Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.23.5 CellMax Life Recent Developments
5.24 Charles River Laboratories
5.24.1 Charles River Laboratories Profile
5.24.2 Charles River Laboratories Main Business
5.24.3 Charles River Laboratories Immuno-oncology Diagnosis Products, Services and Solutions
5.24.4 Charles River Laboratories Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.24.5 Charles River Laboratories Recent Developments
5.25 Chronix Biomedical
5.25.1 Chronix Biomedical Profile
5.25.2 Chronix Biomedical Main Business
5.25.3 Chronix Biomedical Immuno-oncology Diagnosis Products, Services and Solutions
5.25.4 Chronix Biomedical Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.25.5 Chronix Biomedical Recent Developments
5.26 Circulogene
5.26.1 Circulogene Profile
5.26.2 Circulogene Main Business
5.26.3 Circulogene Immuno-oncology Diagnosis Products, Services and Solutions
5.26.4 Circulogene Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.26.5 Circulogene Recent Developments
5.27 Clearbridge BioMedics
5.27.1 Clearbridge BioMedics Profile
5.27.2 Clearbridge BioMedics Main Business
5.27.3 Clearbridge BioMedics Immuno-oncology Diagnosis Products, Services and Solutions
5.27.4 Clearbridge BioMedics Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.27.5 Clearbridge BioMedics Recent Developments
5.28 Clinical Genomics
5.28.1 Clinical Genomics Profile
5.28.2 Clinical Genomics Main Business
5.28.3 Clinical Genomics Immuno-oncology Diagnosis Products, Services and Solutions
5.28.4 Clinical Genomics Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.28.5 Clinical Genomics Recent Developments
5.29 Pfizer
5.29.1 Pfizer Profile
5.29.2 Pfizer Main Business
5.29.3 Pfizer Immuno-oncology Diagnosis Products, Services and Solutions
5.29.4 Pfizer Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.29.5 Pfizer Recent Developments
5.30 Promega
5.30.1 Promega Profile
5.30.2 Promega Main Business
5.30.3 Promega Immuno-oncology Diagnosis Products, Services and Solutions
5.30.4 Promega Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.30.5 Promega Recent Developments
5.31 Protagen Diagnostics
5.31.1 Protagen Diagnostics Profile
5.31.2 Protagen Diagnostics Main Business
5.31.3 Protagen Diagnostics Immuno-oncology Diagnosis Products, Services and Solutions
5.31.4 Protagen Diagnostics Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.31.5 Protagen Diagnostics Recent Developments
5.32 Qiagen
5.32.1 Qiagen Profile
5.32.2 Qiagen Main Business
5.32.3 Qiagen Immuno-oncology Diagnosis Products, Services and Solutions
5.32.4 Qiagen Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.32.5 Qiagen Recent Developments
5.33 Quanterix
5.33.1 Quanterix Profile
5.33.2 Quanterix Main Business
5.33.3 Quanterix Immuno-oncology Diagnosis Products, Services and Solutions
5.33.4 Quanterix Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.33.5 Quanterix Recent Developments
5.34 Rarecells SAS
5.34.1 Rarecells SAS Profile
5.34.2 Rarecells SAS Main Business
5.34.3 Rarecells SAS Immuno-oncology Diagnosis Products, Services and Solutions
5.34.4 Rarecells SAS Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.34.5 Rarecells SAS Recent Developments
5.35 Roche Diagnostics
5.35.1 Roche Diagnostics Profile
5.35.2 Roche Diagnostics Main Business
5.35.3 Roche Diagnostics Immuno-oncology Diagnosis Products, Services and Solutions
5.35.4 Roche Diagnostics Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.35.5 Roche Diagnostics Recent Developments
5.36 Siemens
5.36.1 Siemens Profile
5.36.2 Siemens Main Business
5.36.3 Siemens Immuno-oncology Diagnosis Products, Services and Solutions
5.36.4 Siemens Immuno-oncology Diagnosis Revenue (US$ Million) & (2018-2023)
5.36.5 Siemens Recent Developments
6 North America
6.1 North America Immuno-oncology Diagnosis Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Immuno-oncology Diagnosis Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Immuno-oncology Diagnosis Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Immuno-oncology Diagnosis Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Immuno-oncology Diagnosis Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Immuno-oncology Diagnosis Market Dynamics
11.1 Immuno-oncology Diagnosis Industry Trends
11.2 Immuno-oncology Diagnosis Market Drivers
11.3 Immuno-oncology Diagnosis Market Challenges
11.4 Immuno-oncology Diagnosis Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
